Antibody-Drug Conjugates (ADCs) are a new class of highly potent biological drugs built by attaching a small molecule anticancer drug or another therapeutic agent to an antibody, with either a permanent or a labile linker. The antibody targets a specific antigen only found on target cells. Once it binds to the cell, it triggers internalization of the antibody, together with the drug. This delivers drugs with a very high specificity to the diseased cells, maximizing their efficacy and minimizing systemic exposure, with the associated risk of side effects. At Roche, we have studied ADCs for more than a decade and we have several ADCs in clinical studies for different types of cancer. The ADC technology can be also used outside of cancer-related indications. Depending on the payload which is being attached to the antibody, a variety of biological functions can be influenced. Research areas where such technologies are being explored at ROCHE include onco-immunology and neuroscience.